

OSPEMIFENE tablets (Senshio®) for vulvar and vaginal atrophy in post-menopausal women

The Cheshire and Merseyside Area Prescribing Group does not currently recommend the prescribing of OSPEMIFENE tablets (Senshio®) for vulvar and vaginal atrophy in post-menopausal women.

GREY

Ospemifene is an oral selective oestrogen receptor modulator which is licensed for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women.¹

An in-year application has been received and this recommendation has been prioritised for review by the New Medicines Subgroup.

In the meantime, prescribers should continue to follow national guidance and local formulary choices for the treatment of VVA in post-menopausal women.

- > NICE NG23: [Menopause: diagnosis and management](#) (updated 05 December 2019)
- > NICE Clinical Knowledge Summaries: [Menopause](#) (updated September 2022)
- > Cheshire Formulary Chapter 07.02.01 [Preparations for vaginal and vulval changes](#)
- > Pan Mersey Formulary Chapter 07.02.01 [Preparations for vaginal and vulval changes](#)

References

1. Shionogi. Summary of Product Characteristics; [Senshio 60 mg film-coated tablets](#), 07 February 2023. Accessed 04 October 2023.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.